You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol
|
|---|---|
| Published in |
BMC Cancer, May 2018
|
| DOI | 10.1186/s12885-018-4511-6 |
| Pubmed ID | |
| Authors |
Matthew Richardson, Mark Sidhom, Sarah Gallagher, Mel Grand, David Pryor, Joseph Bucci, Lee Wilton, Sankar Arumugam, Sarah Keats, Jarad M. Martin |
| Abstract |
High Dose Rate Brachytherapy (HDRB) boost is a well-established treatment for prostate cancer (PC). We describe the PROstate Multicentre External beam radioTHErapy Using Stereotactic boost (PROMETHEUS) study. Non-surgical stereotactic techniques are used to deliver similar doses to HDRB boost regimens with a dose escalation sub-study. Eligible patients have intermediate or high risk PC. PROMETHEUS explores the safety, efficacy and feasibility of multiple Australian centres cooperating in the delivery of Prostate Stereotactic Body Radiotherapy (SBRT) technology. A SBRT boost component Target Dose (TD) of 19Gy in two fractions is to be delivered, followed by a subsequent EBRT component of 46Gy in 23 fractions. Once accrual triggers have been met, SBRT doses can be escalated in 1 Gy increments to a maximum of 22Gy in two fractions. Patient safety will also be measured with the rate of both acute and late moderate to severe Gastro-Intestinal (GI) and Genito-Urinary (GU) Common Terminology Criteria for Adverse Events (CTCAE) toxicities as well as patient reported quality of life. Efficacy will be assessed via biochemical control after 3 years. PROMETHEUS aims to generate evidence for a non-surgical possible future alternative to HDRB boost regimens, and introduce advanced radiotherapy techniques across multiple Australian cancer centres. The study was retrospectively registered on the ANZCTR (Australian New Zealand Clinical Trials Registry) with trial ID: ACTRN12615000223538 . |
X Demographics
The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 3 | 25% |
| United States | 3 | 25% |
| Canada | 1 | 8% |
| Belgium | 1 | 8% |
| Spain | 1 | 8% |
| Unknown | 3 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 7 | 58% |
| Members of the public | 4 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 50 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 7 | 14% |
| Student > Bachelor | 6 | 12% |
| Student > Master | 6 | 12% |
| Student > Doctoral Student | 6 | 12% |
| Researcher | 6 | 12% |
| Other | 10 | 20% |
| Unknown | 9 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 46% |
| Nursing and Health Professions | 3 | 6% |
| Computer Science | 2 | 4% |
| Engineering | 2 | 4% |
| Unspecified | 1 | 2% |
| Other | 4 | 8% |
| Unknown | 15 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 February 2024.
All research outputs
#5,154,929
of 25,295,968 outputs
Outputs from BMC Cancer
#1,326
of 8,918 outputs
Outputs of similar age
#90,784
of 337,326 outputs
Outputs of similar age from BMC Cancer
#34
of 190 outputs
Altmetric has tracked 25,295,968 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,918 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 337,326 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 190 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.